- Home
- LFLY vs APVO Comparison
LFLY vs APVO Comparison
Compare LFLY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- APVO
- Stock Information
- Founded
- LFLY 2010
- APVO 2016
- Country
- LFLY United States
- APVO United States
- Employees
- LFLY N/A
- APVO N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- LFLY Technology
- APVO Health Care
- Exchange
- LFLY Nasdaq
- APVO Nasdaq
- Market Cap
- LFLY 3.9M
- APVO 4.4M
- IPO Year
- LFLY N/A
- APVO N/A
- Fundamental
- Price
- LFLY $1.21
- APVO $4.77
- Analyst Decision
- LFLY Strong Buy
- APVO Strong Buy
- Analyst Count
- LFLY 2
- APVO 1
- Target Price
- LFLY $7.59
- APVO $296.00
- AVG Volume (30 Days)
- LFLY 32.7K
- APVO 485.4K
- Earning Date
- LFLY 11-07-2024
- APVO 11-07-2024
- Dividend Yield
- LFLY N/A
- APVO N/A
- EPS Growth
- LFLY N/A
- APVO N/A
- EPS
- LFLY N/A
- APVO N/A
- Revenue
- LFLY $35,868,000.00
- APVO N/A
- Revenue This Year
- LFLY N/A
- APVO N/A
- Revenue Next Year
- LFLY N/A
- APVO N/A
- P/E Ratio
- LFLY N/A
- APVO N/A
- Revenue Growth
- LFLY N/A
- APVO N/A
- 52 Week Low
- LFLY $1.20
- APVO $3.65
- 52 Week High
- LFLY $5.88
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- LFLY 34.88
- APVO 35.34
- Support Level
- LFLY $1.20
- APVO $3.65
- Resistance Level
- LFLY $1.35
- APVO $4.78
- Average True Range (ATR)
- LFLY 0.08
- APVO 1.95
- MACD
- LFLY 0.00
- APVO -0.70
- Stochastic Oscillator
- LFLY 16.92
- APVO 7.55
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.